NIKKEI 225
38,229.11 +155.13 (+0.41%) HANG SENG
18,922.17 +384.36 (+2.07%) CRUDE OIL
79.86 +0.60 (+0.76%) GOLD FUTURES
2,368.80 +28.50 (+1.22%) DOW
39,387.76 +331.36 (+0.85%) Bitcoin GBP
50,134.45 +919.31 (+1.87%)
Conduit Pharmaceuticals Inc. (CDTTW)
| Previous close | 0.0900 |
| Open | 0.0909 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's range | 0.0700 - 0.0998 |
| 52-week range | 0.0700 - 0.0998 |
| Volume | |
| Avg. volume | N/A |
| Market cap | N/A |
| Beta (5Y monthly) | 2.50 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- GlobeNewswire
Conduit Pharmaceuticals Appoints Dr. Joanne Holland as Chief Scientific Officer
Conduit also appoints prominent intellectual property attorney Jeffrey Lindeman as a Consultant Leadership additions underscore Conduit’s commitment to strengthening and broadening its intellectual property portfolio through solid-form technology to maximize future value SAN DIEGO and LONDON, March 19, 2024 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (Nasdaq: CDT) ("Conduit Pharmaceuticals" or "Conduit" or the “Company”) today announced the appointment of Dr. Joanne Holland as Chief Scienti
- GlobeNewswire
Conduit Pharmaceuticals Announces Opening of Prime Laboratory Space in Europe’s Leading Life Sciences Hub
SAN DIEGO and LONDON, March 11, 2024 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (Nasdaq: CDT) ("Conduit Pharmaceuticals" or "Conduit") today announced the opening of cutting-edge laboratory space in Cambridge, United Kingdom, a global centre for research and development for companies at the forefront of life science innovation. This strategic acquisition marks a pivotal milestone for Conduit, positioning the Company for portfolio expansion, enhanced development capabilities, and growth of
- GlobeNewswire
Conduit Pharmaceuticals to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
SAN DIEGO and LONDON, Jan. 31, 2024 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (Nasdaq: CDT) ("Conduit"), a multi-asset, clinical-stage life science company delivering an efficient model for compound development, today announced CEO Dr. David Tapolczay, will be participating in the Oppenheimer 34th Annual Healthcare Life Sciences Conference, being held February 13-14, 2024. Dr. Tapolczay is scheduled to present on Wednesday, February 14, 2024, at 8:00 am EST/13:30 GMT, and will be particip
